Huajin Securities: The quota for refrigerants will take effect in 2025, leading to a continued high prosperity driven by supply and demand resonance.

The third generation quotas have increased, but the overall extent is smaller than the previous guidance.

Zhitong FinanceDec 20 15:34

Guangdong Hec Technology Holding (001318.SZ) controlling shareholder Sunshine Group completed Shareholding, with a total of 2.0015 million shares increased.

Guangdong Hec Technology Holding (001318.SZ) announced that the shareholding plan of its controlling shareholder, Sunshine Group, has been completed by December 2024...

Zhitong FinanceDec 19 18:40

SWHY: The overall performance of the third generation slightly exceeded expectations. The high prosperity of refrigerants continues in the new year.

The structure of the refrigeration Industry and enterprises continues to improve, with strong constraints on future supply. The continuous optimization of the supply-demand structure will lead to a reversal and upward trend in the fluorochemical Industry.

Zhitong FinanceDec 19 14:01

Open-source Securities: Refrigerants may welcome a double hit in the main upward market in 2025.

There is a strong bullish outlook for the refrigerant market to continue, and it is determined that by 2025, under the multiple catalysts of ongoing profit release, accelerated right-side trends, potential seasonal restocking due to low inventory, and rational expectations of policies, the refrigerant Industry may迎来 a major wave of profit and valuation increases.

Zhitong FinanceDec 18 15:17

Guangdong Hec Technology Holding is actively promoting integration for its public listing, establishing a sustainable business model that lays a foundation for development.

Dongyang Guang Pharma has submitted an application to the Hong Kong Stock Exchange, further advancing the absorption merger with HEC CJ PHARM.

lanjinger.comDec 18 10:29

Guangdong Hec Technology Holding's AI-driven first small molecule Innovative Drugs HEC169584 capsules have been approved for clinical use.

On December 16, 2024, Guangdong Hec Technology Holding Co., Ltd. and Hangzhou Hec Technology Holding Co., Ltd. received the "Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the clinical trial of the Class 1 new drug HEC169584 capsules for use in non-alcoholic fatty liver disease.

Zhitong FinanceDec 16 18:34